Placeholder Banner

BIO Comments on FDA Draft Guidance on Development of Therapeutic Protein Biosimilars: Comparative Analytical Assessment and Other Quality-Related Considerations

July 19, 2019

BIO submitted comments on the Food and Drug Administration (FDA) Draft Guidance, Development of Therapeutic Protein Biosimilars: Comparative Analytical Assessment and Other Quality-Related Considerations.

BIO welcomes the guidance on using comparative analytical studies to assess whether a proposed therapeutic protein product is biosimilar to a reference product for purposes of submitting a marketing application under section 351(k) of the Public Health Service (PHS) Act.  In the comments, BIO provides specific changes to clarify the guidance.

Download Full Comments Below
FINAL BIO Comments Comparative Analytical Assessment And Other Quality-Related Considerations
Read the full comments below
Discover More
July 31, 2020 Re: Docket No. FDA–2020-N-0837: Raare Disease Clinical Trial Network; Request for Information. Dear Sir/Madam: The Biotechnology Innovation Organization (BIO) thanks the Food and Drug Administration (FDA or Agency) for the…
July 30, 2020 Re: Docket No. FDA–2019-D-5799: FDA’s Public Meeting, Modernizing the Food and Drug Administration’s Data Strategy. Dear Sir/Madam: The Biotechnology Innovation Organization (BIO) thanks the Food and Drug Administration (FDA or…
The following letter provides BIO’s feedback on a number of regulatory proposals by the Centers for Medicare & Medicaid Services that would ease barriers to use of value-based purchasing arrangements within Medicaid and commercial plans, broaden…